Actelion shakes up its management
Europe’s largest biotech company, Actelion of Basel, is changing its management structure after coming under pressure from investors Elliott Advisors.
In a statement on Tuesday, Actelion said it had appointed Otto Schwarz, head of business strategy and operations at Actelion since 2008, as chief operating officer.
This would allow chief executive Jean-Paul Clozel to focus more on strategic matters, it added.
“Together we are committed to move Actelion to the next stage – advancing value creation for all stakeholders by turning innovation into successful medicines that change patients’ lives,” Clozel said.
“We will also continue to evaluate in-licensing and acquisitions and act decisively when we identify value-adding opportunities.”
Elliott had urged the Swiss biotech group to consider seeking a buyer after a string of product setbacks and had also accused Actelion of pursuing a high-risk strategy that had eroded shareholder value.
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.